Bionano Genomics (BNGO) stock soared 5.16% in the pre-market session on Monday, fueled by the company's preliminary financial results for Q4 2024 and full year 2024, which highlighted growth in its core optical genome mapping (OGM) business and significant cost reduction efforts.
While Bionano expects Q4 2024 revenue to decline around 25% year-over-year to $7.9-$8.1 million, primarily due to the discontinuation of some clinical service products, the company's installed base of OGM systems grew 14% to 371 units in 2024. Additionally, Q4 2024 revenue is projected to increase 30-33% compared to Q3 2024, showcasing recovery in the core business.
Importantly, Bionano's OGM technology continues to gain broader acceptance and recognition, with publications highlighting its utility, guidelines incorporating OGM nomenclature, and the establishment of a Category I CPT code for reimbursement. The company also made strides in reducing costs, with annualized operating expenses expected to decrease by approximately $100 million following restructuring efforts initiated in May 2023. Furthermore, Bionano raised additional capital to extend its cash runway.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。